Giovanni Tramonti- Doctor of Philosophy
- University of Edinburgh
Giovanni Tramonti
- Doctor of Philosophy
- University of Edinburgh
About
12
Publications
464
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
20
Citations
Introduction
Skills and Expertise
Current institution
Publications
Publications (12)
Introduction:
Stereotactic ablative body radiotherapy (SABR) offers patients with stage I non-small-cell lung cancer (NSCLC) a safe, effective radical therapy option. The impact of introducing SABR at a Scottish regional cancer centre was studied.
Methods:
The Edinburgh Cancer Centre Lung Cancer Database was assessed. Treatment patterns and outc...
Background
Approximately thirty thousand people in Scotland are diagnosed with cancer annually, of whom a third live less than one year. The timing, nature and value of hospital-based healthcare for patients with advanced cancer are not well understood. The study's aim was to describe the timing and nature of hospital-based healthcare use and assoc...
Background
Approximately thirty thousand people in Scotland are diagnosed with cancer annually, of whom a third live less than one year. The timing, nature and value of hospital-based healthcare for patients with advanced cancer are not well understood. The aim of this study was to describe patterns of hospital-based healthcare use and associated c...
Background: Several histopathologic classification systems have been described to characterise residual tumour in patients undergoing neoadjuvant chemotherapy (NACT) for breast cancer. Residual Cancer Burden (RCB) has demonstrated prognostic value but requires pathologists to enter specific data items into an external portal to generate a score. Th...
Aims
To externally validate a proposed biochemical definition of cure following low dose rate (LDR) brachytherapy for prostate cancer – 4-year post-implant prostate-specific antigen (PSA) ≤0.2 ng/ml – in a UK population, and report the long-term (10- and 15-year) outcomes for patients stratified by National Comprehensive Cancer Network (NCCN) risk...
Although there have been substantial developments in the analysis of uncertainty in economic evaluations of health care programmes, the development of methods for one-way sensitivity analysis has been notably slower. Conditional incremental net benefit was recently proposed as an approach for implementing probabilistic one-way sensitivity analysis...
